The U.S. Army Medical Materiel Development Activity (USAMMDA) has awarded PrimeVax with the exclusive use rights of the wild type strain of dengue virus used in the PV-001 therapy. Our dengue strain is unique in that its history shows zero confirmed dengue deaths and has an existing safety package on file with FDA. This strain was isolated by Dr. Leon Rosen of the Pacific Biomedical Research Center on the Island of Nauru in 1974. 


The University of Chicago will serve as PrimeVax's dendritic cell manufacturer. Numerous clinical trials spanning the last 20 years and an FDA approved, on-the-market treatment have shown dendritic cells to have a tolerable human safety profile. As our DCs are 3x more potent and have 3x higher volume than industry benchmarks, we expect stronger results in our cancer clinical trials.